Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil

被引：6
|
作者：
Tam, Constantine [1 ,2 ]
Kuss, Bryone [5 ,6 ]
Opat, Stephen [3 ,4 ]
Boulos, Joy [7 ]
Marlton, Paula [8 ,9 ]
机构：
[1] St Vincents Hosp, Dept Haematol, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Dept Haematol, Melbourne, Vic, Australia
[3] Monash Med Ctr, Dept Haematol, Melbourne, Vic, Australia
[4] Monash Univ, Melbourne, Vic, Australia
[5] Flinders Univ S Australia, Dept Haematol, Adelaide, SA, Australia
[6] Flinders Med Ctr, Adelaide, SA, Australia
[7] Roche Prod Ltd, Sydney, NSW, Australia
[8] Princess Alexandra Hosp, Dept Haematol, Brisbane, Qld, Australia
[9] Univ Queensland, Sch Med, Brisbane, Qld, Australia
来源：
INTERNAL MEDICINE JOURNAL | 2017年 / 47卷
关键词：
anti-CD20; monoclonal antibody; rituximab; obinutuzumab; CLL; ILLNESS RATING-SCALE; NON-HODGKIN-LYMPHOMA; RITUXIMAB; TRIAL; CLL; CYCLOPHOSPHAMIDE; FLUDARABINE; SURVIVAL; REGIMEN;
D O I：
10.1111/imj.13493
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Patients with chronic lymphocytic leukaemia (CLL) are generally older, with many considered unfit' for fludarabine-cyclophosphamide-rituximab therapy. In these patients, the combination of obinutuzumab-chlorambucil may be an appropriate therapeutic choice. Obinutuzumab-chlorambucil has been demonstrated to improve overall survival rates compared to chlorambucil alone and to improve progression-free survival and overall response rates compared to rituximab-chlorambucil. This combination can lead to certain toxicities that need to be addressed through appropriate patient selection, pre-medication and management. In this paper, we discuss evidence-based and author-recommended practical management of first-line CLL patients receiving obinutuzumab-chlorambucil.
引用
收藏
页码：5 / 10
页数：6
相关论文
共 50 条
  • [31] OBINUTUZUMAB IN COMBINATION WITH CHLORAMBUCIL IN THE FIRST LINE OF TREATMENT OF ELDERLY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
    Markova, E. E.
    Nikitin, E. A.
    Dmitrieva, E. A.
    Mayorova, S. Yu
    Kochkareva, Yu B.
    Naumova, E., V
    Lugovskaya, S. A.
    Pochtar, M. E.
    Petrenko, A. A.
    Kislova, M., I
    Biderman, B., V
    Sudarikov, A. B.
    Obukhova, T. N.
    Ptushkin, V. V.
    GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2022, 67 (04): : 478 - 490
  • [32] Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial
    Strati, Paolo
    Lanasa, Mark
    Call, Timothy G.
    Leis, Jose F.
    Brander, Danielle M.
    LaPlant, Betsy R.
    Pettinger, Adam M.
    Ding, Wei
    Parikh, Sameer A.
    Hanson, Curtis A.
    Chanan-Khan, Asher A.
    Bowen, Deborah A.
    Conte, Michael
    Kay, Neil E.
    Shanafelt, Tait D.
    LANCET HAEMATOLOGY, 2016, 3 (09): : E407 - E414
  • [33] Safety and Efficacy of Obinutuzumab Plus Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the Green Study
    Stilgenbauer, Stephan
    Ilhan, Osman
    Woszczyk, Darius
    Renner, Christoph
    Mikuskova, Eva
    Boettcher, Sebastian
    Tausch, Eugen
    Moore, Tom
    Tyson, Nicola
    Adamis, Helena
    Leblonde, Veronique
    Bosch, Francesc
    Foa, Robin
    BLOOD, 2015, 126 (23)
  • [34] Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study
    Bosch, Francesc
    Cantin, Guy
    Cortelezzi, Agostino
    Knauf, Wolfgang
    Tiab, Mourad
    Turgut, Mehmet
    Zaritskey, Andrey
    Merot, Jean-Louis
    Tausch, Eugen
    Trunzer, Kerstin
    Robson, Susan
    Gresko, Ekaterina
    Boettcher, Sebastian
    Foa, Robin
    Stilgenbauer, Stephan
    Leblond, Veronique
    LEUKEMIA, 2020, 34 (02) : 441 - 450
  • [35] Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study
    Francesc Bosch
    Guy Cantin
    Agostino Cortelezzi
    Wolfgang Knauf
    Mourad Tiab
    Mehmet Turgut
    Andrey Zaritskey
    Jean-Louis Merot
    Eugen Tausch
    Kerstin Trunzer
    Susan Robson
    Ekaterina Gresko
    Sebastian Böttcher
    Robin Foà
    Stephan Stilgenbauer
    Véronique Leblond
    Leukemia, 2020, 34 : 441 - 450
  • [36] Continuous High-Dose Chlorambucil in Previously Untreated Patients with Chronic Lymphocytic Leukemia-Single-Center Experience
    Basic-Kinda, Sandra
    Aurer, Igor
    Dujmovic, Dino
    Radman, Ivo
    Sertic, Dubravka
    Dubravcic, Klara
    Gjadrov-Kuvezdic, Koraljka
    Batinic, Drago
    Sucic, Mirna
    Labar, Boris
    BLOOD, 2009, 114 (22) : 936 - 937
  • [37] Cost-Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy
    Paquete, Ana Teresa
    Miguel, Luis Silva
    Becker, Ursula
    Pereira, Catarina
    Pinto, Carlos Gouveia
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2017, 15 (04) : 501 - 512
  • [38] Cost-Effectiveness Analysis of Obinutuzumab Versus Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
    Reyes, Carolina
    Gazauskas, Gregory
    Becker, Ursula
    Moreno, Santiago
    Veenstra, David L.
    BLOOD, 2014, 124 (21)
  • [39] Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Previously Untreated Chronic Lymphocytic Leukemia
    Shah, Arpita
    ANNALS OF PHARMACOTHERAPY, 2014, 48 (10) : 1356 - 1361
  • [40] USE OF CHLORAMBUCIL AND STEROIDS IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA
    GALTON, DA
    DACIE, JV
    SZUR, L
    WILTSHAW, E
    BRITISH JOURNAL OF HAEMATOLOGY, 1961, 7 (01) : 73 - &
12345